Literature DB >> 26655600

Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property.

Kefu Liu1, Yutong Liu2, Lingyun Li3, Peibin Qin4, Javed Iqbal1, Yulin Deng5, Hong Qing6.   

Abstract

The risk of tauopathies depends in part on the levels and modified composition of six Tau isoforms in the human brain. Abnormal phosphorylation of the Tau protein and the shift of the ratio of 3R Tau to 4R Tau are presumed to result in neurofibrillary pathology and neurodegeneration. Glycation has recently been linked to dementia and metabolic syndrome. To determine the contribution of Tau protein glycation and phosphorylation on Tau aggregation propensity, the assembled kinetics were examined in vitro using Thioflavin T fluorescence assays. We found that glycation and phosphorylation have different effects on aggregation propensity in different Tau isoforms. Different Tau proteins play important parts in each tauopathies, but 3R0N, fetal Tau protein, has no effect on tauopathies. Conversely, 4R2N has more modified sites and a higher tendency to aggregate, playing the most important role in 4R tauopathies. Finally, Glycation, which could modulate Tau phosphorylation, may occur before any other modification. It also regulates the 3R to 4R ratio and promotes 4R2N Tau protein aggregation. Decreasing the sites of glycation, as well as shifting other Tau proteins to 3R0N Tau proteins has potential therapeutic implications for tauopathies.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Glycation; Phosphorylation; Post-translational modification sites; Tau aggregation; Tau isoforms; Tauopathies

Mesh:

Substances:

Year:  2015        PMID: 26655600     DOI: 10.1016/j.bbadis.2015.12.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  16 in total

1.  Protein Glycation by Glyoxal Promotes Amyloid Formation by Islet Amyloid Polypeptide.

Authors:  Yi-Hsuan Hsu; Yun-Wen Chen; Meng-Hsin Wu; Ling-Hsien Tu
Journal:  Biophys J       Date:  2019-05-21       Impact factor: 4.033

Review 2.  Tau Proteins and Tauopathies in Alzheimer's Disease.

Authors:  Fong Ping Chong; Khuen Yen Ng; Rhun Yian Koh; Soi Moi Chye
Journal:  Cell Mol Neurobiol       Date:  2018-01-03       Impact factor: 5.046

3.  Tau in Alzheimer's Disease: Pathological Alterations and an Attractive Therapeutic Target.

Authors:  Jian-Lan Gu; Fei Liu
Journal:  Curr Med Sci       Date:  2021-01-11

Review 4.  Prion-Like Propagation of Post-Translationally Modified Tau in Alzheimer's Disease: A Hypothesis.

Authors:  Shweta Kishor Sonawane; Subashchandrabose Chinnathambi
Journal:  J Mol Neurosci       Date:  2018-07-07       Impact factor: 3.444

Review 5.  Advanced Glycation End-Products (AGEs): Formation, Chemistry, Classification, Receptors, and Diseases Related to AGEs.

Authors:  Aleksandra Twarda-Clapa; Aleksandra Olczak; Aneta M Białkowska; Maria Koziołkiewicz
Journal:  Cells       Date:  2022-04-12       Impact factor: 7.666

Review 6.  Insight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profiling.

Authors:  Sunil S Adav; Siu Kwan Sze
Journal:  Mol Brain       Date:  2016-11-03       Impact factor: 4.041

7.  Epigallocatechin-3-gallate modulates Tau Post-translational modifications and cytoskeletal network.

Authors:  Shweta Kishor Sonawane; Subashchandrabose Chinnathambi
Journal:  Oncotarget       Date:  2021-05-25

Review 8.  Lysine-Directed Post-translational Modifications of Tau Protein in Alzheimer's Disease and Related Tauopathies.

Authors:  Christiana Kontaxi; Pedro Piccardo; Andrew C Gill
Journal:  Front Mol Biosci       Date:  2017-08-11

Review 9.  Tau Structures.

Authors:  Jesus Avila; Juan S Jiménez; Carmen L Sayas; Marta Bolós; Juan C Zabala; Germán Rivas; Felix Hernández
Journal:  Front Aging Neurosci       Date:  2016-11-08       Impact factor: 5.750

Review 10.  Dichotomous role of microtubule associated protein tau as a biomarker of response to and a target for increasing efficacy of taxane treatment in cancers of epithelial origin.

Authors:  Maria V Barbolina
Journal:  Pharmacol Res       Date:  2021-03-30       Impact factor: 10.334

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.